Merrimack Pharma (MACK) Misses Q4 EPS by 10c

Merrimack Pharma (NASDAQ: MACK) reported Q4 EPS of ($0.41), $0.10 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $21.42 million versus the consensus estimate of $26.58 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Citi cuts Weibo stock rating to Neutral, lowers price target
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue